CAGGIANO, VALERIA
 Distribuzione geografica
Continente #
EU - Europa 2.487
AS - Asia 1.981
NA - Nord America 1.754
SA - Sud America 336
AF - Africa 124
OC - Oceania 3
Totale 6.685
Nazione #
US - Stati Uniti d'America 1.685
IT - Italia 1.110
RU - Federazione Russa 703
SG - Singapore 632
CN - Cina 512
VN - Vietnam 316
BR - Brasile 257
HK - Hong Kong 148
KR - Corea 147
IE - Irlanda 122
DE - Germania 116
GB - Regno Unito 87
FR - Francia 86
FI - Finlandia 71
IN - India 67
NL - Olanda 67
ZA - Sudafrica 61
MX - Messico 30
CA - Canada 29
AR - Argentina 27
BD - Bangladesh 23
TR - Turchia 21
SE - Svezia 20
IQ - Iraq 17
JP - Giappone 15
PL - Polonia 15
AT - Austria 14
CI - Costa d'Avorio 14
KE - Kenya 14
CZ - Repubblica Ceca 13
VE - Venezuela 13
ES - Italia 12
MA - Marocco 12
SA - Arabia Saudita 12
UZ - Uzbekistan 10
EC - Ecuador 9
CL - Cile 8
PK - Pakistan 8
CO - Colombia 7
ID - Indonesia 7
PE - Perù 7
TN - Tunisia 7
CH - Svizzera 6
DZ - Algeria 6
LT - Lituania 6
PH - Filippine 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
PY - Paraguay 5
AL - Albania 4
CR - Costa Rica 4
IR - Iran 4
JO - Giordania 4
BH - Bahrain 3
BY - Bielorussia 3
DK - Danimarca 3
EG - Egitto 3
LB - Libano 3
NP - Nepal 3
PT - Portogallo 3
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
ET - Etiopia 2
GR - Grecia 2
GY - Guiana 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
TM - Turkmenistan 2
AM - Armenia 1
CG - Congo 1
CM - Camerun 1
GI - Gibilterra 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
SV - El Salvador 1
TG - Togo 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 6.685
Città #
Dallas 502
Singapore 399
Hefei 247
Moscow 210
Milan 178
San Jose 168
Santa Clara 156
Seoul 147
Hong Kong 140
Dublin 118
Ashburn 115
Ho Chi Minh City 109
Beijing 84
Rome 83
Hanoi 71
New York 65
Los Angeles 63
Council Bluffs 61
Siena 59
Johannesburg 58
Lauterbourg 56
Florence 49
Munich 45
The Dalles 43
Helsinki 33
Orem 32
Bengaluru 29
Chicago 27
São Paulo 27
Lappeenranta 26
Da Nang 24
Southend 24
Redondo Beach 22
Turin 21
Frankfurt am Main 20
Buffalo 18
Bologna 17
Nuremberg 17
Chennai 16
London 16
Bari 15
Haiphong 15
Naples 15
Abidjan 14
Tokyo 14
Warsaw 14
Amsterdam 13
Mexico City 13
Perugia 13
Düsseldorf 12
Houston 12
Lucca 12
Padova 12
Portsmouth 12
Turku 12
Manchester 11
Reggio Emilia 11
Livorno 10
Messina 10
Montreal 10
Monza 10
Atlanta 9
Denver 9
Fairfield 9
Istanbul 9
Sutri 9
Tashkent 9
Bergamo 8
Olomouc 8
Palermo 8
Stockholm 8
Verona 8
Wilmington 8
Baghdad 7
Biên Hòa 7
Brescia 7
Curitiba 7
Genoa 7
Hải Dương 7
Pisa 7
Seattle 7
Venice 7
Catania 6
Guangzhou 6
Modena 6
Mumbai 6
Parma 6
Ravenna 6
Salerno 6
San Francisco 6
Toronto 6
Vienna 6
Acerra 5
Ankara 5
Biella 5
Boston 5
Brindisi 5
Cascina 5
Fortaleza 5
Jeddah 5
Totale 4.120
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 862
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 220
A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project 216
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome 199
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) 195
Development and implementation of the AIDA international registry for patients with non-infectious uveitis 195
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 192
Development and implementation of the AIDA International Registry for patients with Behçet's disease 190
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network 165
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry 161
Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry 160
Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders 152
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases 148
Development and implementation of the AIDA international registry for patients with non-infectious scleritis 148
Comparing biologic options for the management of Behcet's disease-related uveitis 145
Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis: Data From the AIDA Network Uveitis Registry 144
Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome 140
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 137
Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry 132
Development and implementation of the AIDA international registry for patients with Still's disease 131
Efficacy and safety of adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the International AIDA Network Uveitis Registry 130
Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry 130
The diagnostic role of pathergy test in patients with Behçet’s disease from the Western Europe 129
Ocular Manifestations in Juvenile Behçet’s Disease: A Registry-Based Analysis from the AIDA Network 129
Development and implementation of the international AIDA network spondylarthritis registry 127
Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry 124
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still's Disease Registry 120
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network 120
The current status of biological treatment for uveitis 120
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 118
Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA network registries 115
The role of biologic agents in the management of pediatric-onset noninfectious posterior scleritis 115
Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries 110
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 107
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry 100
Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: a multicenter study from the AIDA Network PFAPA syndrome registry 94
Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry 88
The autoinflammatory diseases alliance registry of monogenic autoinflammatory diseases 87
Development and implementation of the International AIDA Network Castleman’s disease registry 85
The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry 84
Systemic auto-inflammatory manifestations in patients with spondyloarthritis 81
Imaging findings in patients with axial spondyloarthritis presenting with recurrent fever attacks: data from the international AIDA network spondyloarthritis registry 75
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry 73
IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry 56
Unfolding dermatological spectrum of Still’s disease: a cohort study from the International AIDA Network Still’s Disease Registry 55
Predictors of uveitic macular edema and functional prognostic outcomes: real-life data from the international AIDA Network uveitis registry 55
The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry 53
Incidence and Predictors of Ocular Complications in Pediatric-Onset Uveitis: Data from the AIDA Network Uveitis Registry 46
Evaluation of Myocarditis in Patients With Still Disease: Clinical Findings From the Multicenter International AIDA Network Still Disease Registry 39
Reproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry 34
VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries 17
Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries 17
Totale 6.865
Categoria #
all - tutte 17.764
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.764


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 6 2 8
2021/202236 2 6 3 2 2 0 1 5 3 1 5 6
2022/2023109 2 3 6 3 0 3 2 1 44 5 26 14
2023/2024566 9 16 40 39 55 90 111 54 14 36 49 53
2024/20251.902 139 73 189 116 181 126 84 139 157 97 156 445
2025/20264.177 324 595 488 589 725 161 601 178 221 295 0 0
Totale 6.865